This inventor holds 4 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Trefoil Therapeutics, Inc., Eb Technologies, LLC. Active years: 2020-2026.
Company Filing History:
Years Active: 2020-2026
Title: David Eveleth: Innovator in Fibroblast Growth Factor Technologies
Introduction
David Eveleth is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of modified fibroblast growth factors (FGFs). With a total of 4 patents to his name, Eveleth's work has the potential to impact various therapeutic applications.
Latest Patents
Eveleth's latest patents include groundbreaking innovations such as "Recombinant modified fibroblast growth factors and therapeutic uses thereof." This patent describes modified FGF polypeptides, pharmaceutical compositions, and methods for treating conditions that benefit from FGFs. Another notable patent is "Modified fibroblast growth factors for the treatment of ocular disorders," which outlines the use of modified FGFs in treating ocular diseases and disorders.
Career Highlights
Throughout his career, David Eveleth has worked with several companies, including Trefoil Therapeutics, Inc. and Eb Technologies, LLC. His expertise in fibroblast growth factors has positioned him as a key player in the biotechnology sector.
Collaborations
Eveleth has collaborated with notable individuals in his field, including Jennifer Jenkins-Eveleth and Amuthakannan Subramaniam. These collaborations have further enhanced his research and development efforts.
Conclusion
David Eveleth's innovative work in the field of fibroblast growth factors showcases his commitment to advancing medical science. His patents and collaborations reflect a dedication to improving therapeutic options for various health conditions.